-
BP8 Sources Bird’s Nest Products from Chinese State-Owned Conglomerate China National Pharmaceutical Group Corporation (Commonly Known as Sinopharm)
06 Jun 2024 04:43 GMT
…
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced … U.S. Food and Drug Administration (FDA) on May 28, 2021 … . 24 Unmet medical need remains high and treatment options are limited … helped to establish the biotechnology industry and remains on the …
-
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
03 Jun 2024 00:38 GMT
… Encouraging Data from Prior Trials
“We are eager … and carboplatin/pemetrexed in INSIGHT-003 has … ;KEYTRUDA has revolutionized the treatment landscape in NSCLC and … Drug Administration (FDA). About Immutep
Immutep is a clinical-stage biotechnology …
-
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
02 Jun 2024 19:04 GMT
… New England Journal of Medicine.
Results showed TAGRISSO … treatment. For patients receiving TAGRISSO in combination with pemetrexed … FDA-approved test
TAGRISSO is indicated in combination with pemetrexed … II trials, and the SAFFRON Phase III trial, which …
-
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
01 Jun 2024 07:45 GMT
… carboplatin and pemetrexed) for the first-line treatment of adult … New Drug Application (NDA) to the U.S. FDA … ; Development, LLC, and Janssen Biotech, Inc., are Johnson … Randomized, Controlled Trial. 2023 European Society for Medical Oncology. October …
-
Johnson & Johnson Submits Application To The European Medicines Agency Seeking Approval Of Subcutaneous Formulation Of RYBREVANT®▼ (Amivantamab) For The Treatment Of Patients With EGFR-Mutated Non-Small Cell Lung Cancer
31 May 2024 23:49 GMT
… Johnson & Johnson Innovative Medicine.“The positive data presented … (carboplatin and pemetrexed) for the treatment of adult patients … studied in multiple clinical trials in NSCLC, including: … Global, Randomized, Controlled Trial. 2024 American Society of …
-
RYBREVANT®▼ (Amivantamab) Plus Lazertinib Shows Longer Progression-Free Survival Versus Osimertinib In The First-Line Treatment Of Patients With High-Risk EGFR-Mutated Non-Small Cell Lung Cancer
31 May 2024 22:13 GMT
… with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with … being studied in multiple clinical trials in NSCLC, including: The Phase … , Global, Randomized, Controlled Trial. 2023 European Society for Medical Oncology. 23 October …
-
FDA Prioritizes Keytruda Chemotherapy Mesothelioma Combo
30 May 2024 23:12 GMT
… of this development, stating, “Malignant pleural mesothelioma … . They also received pemetrexed and cisplatin (or … malignant pleural mesothelioma. Doctors diagnosed an estimated … treatment options for patients with difficult-to-treat cancers.
Medically …
-
US FDA grants priority review status to Merck's sBLA for Keytruda plus chemotherapy to treat metastatic malignant pleural mesothelioma
30 May 2024 09:05 GMT
… and Drug Administration (FDA) has … trial (ClinicalTrials.gov, NCT02784171) sponsored and conducted by Canadian Cancer Trials … trial. The trial evaluated Keytruda plus chemotherapy versus chemotherapy alone for the treatment … ), or Pemetrexed and cisplatin …
-
FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma
29 May 2024 16:22 GMT
… .227/KEYNOTE-483 trial (NCT02784171), in which the … the FDA to help bring [pembrolizumab] as a potential treatment option … that from previously reported trials.1
FDA grants priority review … ) study of cisplatin/pemetrexed (CP) with or without …
-
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
29 May 2024 11:33 GMT
… Food and Drug Administration (FDA) has … trial (ClinicalTrials.gov, NCT02784171) sponsored and conducted by Canadian Cancer Trials … pemetrexed and platinum chemotherapy, is indicated for the first-line treatment … impact of pharmaceutical industry regulation …